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ABSTRACT – With one of the oldest surviving cultures in the world, Australian Aboriginal people have 
developed immense knowledge about the diverse Australian flora. Western scientific investigation of some 
Australian Aboriginal medicinal plants has demonstrated interesting pharmacological activities and 
chemistry, however the majority of these species have not yet been extensively examined. We argue that 
research that is locally initiated and driven by Indigenous traditional owners in collaboration with Western 
scientists has significant potential to develop new plant-based products. Locally driven medicinal plants 
research in which traditional owners work as researchers in collaboration with University-based colleagues 
in the investigation of medicines rather than “stakeholders” or “informants” is one model that may be used 
in characterising plants with the potential to be developed into sustainable plant-based medicinal products 
with commercial value. Our team has taken this approach in research located both on traditional homelands 
and in the laboratory.  Research being conducted by the University of South Australia and Chuulangun 
Aboriginal Corporation has led to patent filing for protection of intellectual property associated with novel 
compounds and extracts with the potential for development through cosmetic, complementary medicine and 
pharmaceutical routes. Ongoing research is examining the commercial developmental pathways and 
requirements for product development in these spaces. This review will address the opportunities that might 
exist for working in partnership with Australian Indigenous communities, some of the scientific knowledge 
which has been generated so far from our work together and the lessons learnt since the inception of the 
collaboration between the Chuulangun Aboriginal Corporation and scientists from the University of South 
Australia. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may 
comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
This article provides a philosophical and cultural 
perspective of an Australian based Indigenous-
guided natural product medicine project, which is 
complemented with a discussion of some of the 
Western scientific research outcomes. The reader 
should note that aspects of the discussion included 
in this manuscript may not necessarily reflect the 
beliefs and opinions of individual (specific) 
Australian Aboriginal communities but should 
rather be viewed as a broader, more generalized 
perspective. 
Australian Indigenous peoples have occupied 
the Australian continent for an estimated 40,000-
50,000 years (1) and during that time have 
developed a profound understanding of the 
Australian landscape and processes of 
biodiversity conservation management. At the 
time of European settlement in 1788, early 
explorers were surprised at how such a landscape 
had been kept curated in an almost pristine-like 
manner (2). Complex traditional land 
management practices used by Indigenous 
peoples helped to create the natural landscape of 
Australia prior to European arrival (3-6).  
Unfortunately, as Western agricultural practices 
and population increase began to take effect, so 
did an imbalance of the once well-managed 
country (homelands).  
In some regions of remote Australia, the 
influence of Western society and governance has 
resulted in a shift in the number of Indigenous 
people living on traditional homelands, with many 
relocating to major urban centres, resulting in a 
loss of heritage and traditions of their ancestors 
(7).  Ultimately, this will lead to a decline in the 
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intergenerational transfer of traditional knowledge 
that has been developed and maintained over the 
millennia. While it may not be immediately 
apparent, a failure to address this issue has 
consequences for Aboriginal peoples in terms of a 
loss of language, culture and identity (8). 
Moreover, traditional management practices 
which have sustained the unique biodiversity that 
exists today on the Australian continent will also 
be threatened (6, 9, 10).  
Traditional medicine systems form one aspect 
of Australian Indigenous traditional knowledge. It 
should be noted that these systems are highly 
complex and may vary between different 
Indigenous groups across the continent (11-13). 
These systems incorporate mostly the use of 
plants for the purpose of treating disease but may 
also see the use of other natural resources (e.g. 
animals such as Witchetty grub, Endoxyla 
leucomochla and minerals and clays) (12-14). 
Traditionally there has been oral transmission of 
this knowledge (and traditional knowledge in 
general) which may come in the form of stories, 
singing and dancing ceremonies. Due to an 
absence of a written language, physical recordings 
of this knowledge prior to European colonisation 
of Australia do not exist. Therefore traditional 
owner groups are undertaking and exploring ways 
to preserve knowledge. One possible way is 
through collaborative projects with Western-based 
researchers working in areas of botany, ecology, 
pharmacology and anthropology to record 
knowledge and investigate plants from a Western 
scientific perspective for pharmacological 
activity. 
This review will address the opportunities that 
might exist for developing medicinal products 
from the Australian flora and working in 
partnership with Australian Indigenous 
communities. Our own experiences of working in 
an ongoing collaborative research initiative 
between Indigenous researchers based on their 
traditional homelands in Cape York Peninsula, 
Queensland and University-based researchers will 
be presented. An emphasis is placed on reviewing 
the Western scientific outcomes from this research 
to highlight the therapeutic opportunities that 
exist in the investigation of Australian Aboriginal 
medicinal plants in addition to preserving 
medicinal plant knowledge.  
 
The Opportunity 
Australia is listed as one of the Earth’s 
megadiverse countries by Conservation 
International and the United Nations Environment 
Program's World Conservation Monitoring 
Centre.  Fire regimes have been a major tool to 
ensure a balance and survival of the approximate 
18,500 (± 1.0 %) native flowering plant species 
that are found in Australia (15). Australia 
possesses one of the highest levels of species 
richness and endemism in the world. Areas 
containing both species richness and endemism 
are classified as hotspots, with several having 
been identified by Crisp et al. (16) from work 
reported during the early 2000s. These include 
south-west Western Australia, Cape York 
Peninsula (Queensland), Border-Ranges 
(Queensland – New South Wales border), North 
Kimberly, Kakadu-Alligator Rivers (Northern 
Territory), Kangaroo Island (South Australia) and 
Tasmania. With such rich biodiversity, the notion 
that this could translate into novel chemical 
diversity of natural products produced by these 
plants with biological activities that are unique in 
their mode of action is a tantalising prospect. 
Many plants have been used by different clans 
of Indigenous people throughout Australia as a 
means of primary treatment of ailment and 
disease. Whilst Indigenous populations rely on 
access to conventional (Western) medicines, the 
use of more traditional approaches remains. One 
important distinction between Western and 
Traditional medicine is the philosophy behind 
how the illness and disease is combatted (17). 
Indigenous philosophy as it relates to medicinal 
plants sees the whole plant (or plant part) and the 
combination of constituents found within it as the 
active ingredient, in contrast to Western medicine, 
where generally a single chemical entity is used 
as the medicine (14, 18, 19).  
It would be a disappointing scenario if the 
knowledge of medicinal plant use developed by 
Australian Indigenous populations was lost. The 
opportunity to help ensure that this information is 
available for generations to come and work with 
communities in achieving this would be foolish to 
ignore. Before such ventures can take place 
however, an understanding is required to realise 
why communities might not want to work with 
Western researchers. 
Part of the reluctance of indigenous 
communities to work with Western scientists is 
historical and relates to the post-colonisation 
treatment as non-equal, including the removal of 
Indigenous populations from their native lands 
and into Government controlled reserves initiated 
by Aboriginal Protection Acts (e.g. The 
Aboriginals Protection and Restriction of the Sale 
of Opium Act 1897) (20). In terms of medicinal 
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plant research in the contemporary setting, there 
are two aspects to consider. The first of these 
relates to the recording of traditional knowledge 
in the public domain. Whilst we are proponents to 
approaches which help to preserve traditional 
knowledge as it relates to Indigenous medicinal 
plants use, publishing such works into the public 
domain, does raise the question of whether this 
could indeed be detrimental to communities in the 
long-term. While in many cases this may have 
been done with good intentions (i.e. to preserve 
knowledge in written form), researchers may use 
this knowledge without talking to, or recognising 
the owners of the knowledge or return of benefits 
to the communities to which the genetic resources 
belong (21). An important factor to consider in 
relation to this is where Indigenous people stand 
on their intellectual property rights once 
information is released into the public domain. 
One option for overcoming this challenge is 
develop initiatives which restrict public access to 
recorded traditional knowledge so that Indigenous 
people benefit by legally protecting their 
knowledge (in accordance with Western legal 
systems) as well as recording it for the betterment 
of future generations. The second aspect relates to 
the scientific testing of plants and medicinal 
product development that is based upon 
traditional knowledge, where outcomes are 
published without Indigenous involvement or 
acknowledgement. This precedence has made it 
somewhat more challenging to establish 
collaborative research ventures for new groups as 
a result of a lack of trust towards outsiders and 
western researchers (22).  
In recent years, there has been a positive shift 
towards creating collaborative research initiatives 
with Indigenous communities in which all parties 
participate and benefit. This is most likely as a 
result of the establishment of the Convention on 
Biological Diversity and the subsequent protocols 
and guidelines governed by this instrument both 
abroad (e.g. Bonn Guidelines (23), Nagoya 
Protocol (24)) and locally (25). Whilst it is 
common for Western researchers to want to learn 
from Indigenous peoples, there is a strong desire 
of Indigenous communities wanting to understand 
what Western scientific principles can tell them 
about their natural resources and how this 
knowledge might be harnessed for the benefit of 
their people. A two-way exchange of information 
approach is helping to move beyond the 
dichotomy of Indigenous versus scientific 
paradigms that has plagued the area for a long 
time (26). In constructing collaborative research 
with Indigenous people, it should be made 
apparent that traditional knowledge is Indigenous 
technology (2). Accordingly, Indigenous people 
have their own effective science and resource use 
practices; a concept that is finally gaining 
practical recognition (27).  
 
  
 
 
Figure 1. Approaches to Aboriginal medicine research in Australia. 
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Previous Medical Plant Research in Australia 
 
Research centred on the Western scientific 
properties of Australian Aboriginal medicinal 
plants, namely the chemistry, pharmacology and 
mode of actions has been predominantly carried 
out within academic institutional environments. 
Figure 1 illustrates general pathways for 
researching Australian Aboriginal medicines, 
being either affiliated or non-affiliated with an 
Indigenous community(ies).  
Some of the earliest research carried out on 
Australian flora was initiated by the CSIRO 
during the 1940s in response to World War II and 
the need to find sources for new drugs of plant 
origin at the time (28). Several thousand plant 
species were screened for their alkaloid content 
over an approximate 30 year period and 
subsequent screening for anti-tumour activity as 
part of an agreement with the Cancer 
Chemotherapy National Service Centre, National 
Institutes of Health (USA). Alkaloid secondary 
metabolites as stock poisons or with anti-tumour 
activities were of major interest to the CSIRO. 
However, a loosely organised collaboration of 
phytochemists from Australian universities 
stemming from this initiative were involved in 
identifying a broad range of other chemical 
classes including terpenoids, flavonoids, steroids 
and other phenolics. Many of the compounds 
were isolated and identified for the first time – 
highlighting the novel chemical diversity of 
natural products produced by the unique 
Australian flora.  However, in general these 
studies lacked any pharmacological aspect. 
Needless to say, therefore, the chemodiversity and 
pharmacological potential of the large number of 
plant species screened was still far from 
understood. 
There are still a large number of plants used 
by Australian Indigenous communities for 
medicinal purposes (either recorded in the 
literature or not in the public domain) that have 
not been examined from Western scientific 
perspectives. Previous projects like the CSIRO 
type and other more recent ones (29) involved 
little if any consultation with Indigenous 
communities. Hence opportunities remain for 
current and future research projects to operate as 
collaborative, ethnobotanical-guided initiatives to 
discover a wealth of untapped potential from 
traditionally used plants. 
Some research approaches may involve use of 
published literature sources and Aboriginal 
pharmacopoeias as a means guiding of plant 
selection for Western scientific studies of the 
native flora (30-34). This form of research, which 
has been undertaken in the past by some of the 
authors of this review, is driven and published 
purely by Western researchers with little, if any 
scope for this avenue to provide benefits back to 
the communities whose knowledge, culture and 
spirituality are embedded in those resources. 
Alternatively, where an affiliation initially exists, 
this may be short-lived for a variety of reasons 
with Indigenous peoples then simply serving as 
informants of traditional knowledge which guides 
the research, and become bystanders of the 
research process as Western researchers continue 
to carry on their investigations (35). Another 
approach can be research collaborations that are 
initiated and driven by the Indigenous 
communities themselves and that are in line with 
local aspirations for natural resource management 
and preservation of traditional knowledge.  
There are a number of Australian Aboriginal 
traditional owners who are striving hard to better 
their communities’ livelihoods through the 
initiation of different ventures which capitalise on 
the strengths of ‘living off the land’. The 
Australian Human Rights Commission in its 2010 
Social Justice Report, acknowledges the 
economic viability of homelands and particularly 
resource management projects which generate 
opportunities for conservation and economic 
development for traditional owners living on 
homelands (36). On homelands there is an 
enormous potential for traditional owners to 
develop economic opportunities based in 
sustainable land and resource management which 
includes river and water management, 
biodiversity conservation, carbon sequestration, 
fire control, quarantine, ecotourism and 
sustainable harvest of plant products. Such land 
management based activities are sometimes 
referred to as belonging to the ‘conservation 
economy’ or ‘hybrid economy’ which supports 
Aboriginal aspirations to live and work on 
country (37). 
We argue that traditional owners of this 
calibre and who have relevant vision and foresight 
will have a greater bearing on the survival of their 
culture and identity than will Western researchers 
simply wanting to test plants based on valuable 
traditional ecological knowledge without research 
partnerships and the sharing of benefits. 
Before discussing the collaborative project to 
which the authors of this review belong, it should 
be highlighted that there are other academic 
groups in Australia who are involved in 
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innovative Indigenous engagement research 
activities where medicinal plants and knowledge 
are of central focus. One such group includes 
researchers from the Indigenous Bioresources 
Research Group at Macquarie University, New 
South Wales who work with Aboriginal 
communities of Northern New South Wales (38). 
Part of the strategy for collaborating with 
Indigenous people from this area of Australia is 
stimulated by the fact that there has been little 
focus on New South Wales communities in 
previous studies which have documented the 
preparation and use of medicinal plants of 
Australian Aboriginal communities (39). A strong 
emphasis of the groups work is centred on the 
detailed recording of ethnobotanical data from 
communities within this region as a means of 
preserving the invaluable customary medicinal 
knowledge of these people (40). Additionally, 
they have also developed educational activities 
for school children in these areas as part of an 
initiative know as Indigenous Science Education 
Program (ISEP) (41). 
 A partnership between researchers from 
Griffith University and members of The 
Jarlmadangah Burru Aboriginal Community from 
the Kimberly region, North Western Australia has 
developed agreements on access and benefit-
sharing arrangements. This research partnership, 
has resulted in filing of a patent co-owned by each 
party for the protection of the intellectual property 
relating to novel analgesic compounds isolated 
from a plant traditionally known as the Marjala 
plant (Barringtonia acutangula) (42, 43). 
 
Kuuku I’YU Medicinal Plant Project 
 
The homelands of Kuuku I’yu Northern Kaanju 
people are located in Cape York Peninsula, 
Queensland, Australia and encompass some 
840,000 hectares. Their country is centred on the 
upper Wenlock and Pascoe Rivers and is bordered 
by Archer River in the South, extending to Olive 
River in the North and from Lockhart Valley in 
the East, stretching to Embley Range in the West.  
For Kuuku I’yu Northern Kaanju people simply 
being partners or stakeholders in land and 
resource management projects run by mainstream 
agencies is not adequate. Instead they strive for a 
more locally driven and self-determined approach 
to the way in which they manage their land and 
resources (44). The origins of the collaboration 
between Chuulangun Aboriginal Corporation and 
University of South Australia researchers has in 
part been built on a reformed model of natural 
resource management (NRM) practices developed 
by The Corporation (44) (See Figure 2). One area 
of prioritisation in this framework is centred on 
the sustainable use and development of 
traditionally used medicinal and aromatic plants. 
To achieve these priorities Northern Kaanju 
traditional owners invited Western researchers to 
join them in initiating projects that would 
investigate the chemical and pharmacological 
properties of plants used in the traditional 
medicine system of Kuuku I’yu Northern Kaanju 
ancestors. 
The manner by which this project was 
established often gives a reaction of surprise by 
outsiders due to the unusual situation of 
Indigenous researchers initiating partnerships with 
Western researchers, rather than by Western 
researchers. It is this contrasting approach 
however that is leading to novel Western 
scientific knowledge and understanding of these 
resources and treading new territory in terms of 
the recognition and benefits being distributed 
back to the community.  
 
 
 
 
 
Figure 2 Model for Sustainable Natural Resource 
Management (NRM) on Kuuku I’yu Northern Kaanju 
traditional homelands. (Reproduced with permission 
from Chuulangun Aboriginal Corporation). 
 
The development and intellectual property 
considerations of this collaborative research 
model as one approach for Indigenous-initiated 
and driven Australian medicinal plant research 
has been covered in detail elsewhere (35). 
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The remainder of this review will examine the 
findings of the Western-science from this work, 
how it complements the Indigenous science 
(traditional knowledge) of the plants investigated 
(as opposed to confirming/dismissing the validity 
of the knowledge) and what it means in terms of 
moving forward.  
As part of an Australian Research Council 
Linkage grant (2006-2009), several plants 
collected from Kuuku I’yu Northern Kaanju 
homelands were screened for their anti-
inflammatory properties using an acute mouse ear 
oedema model (male Balb/C mice). This 
particular model uses the tumour-promoting 
phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (TPA) to induce inflammation of the ear. It 
is characterised by a marked increase in redness 
and swelling, where ear thickness is measured as 
an endpoint for inflammation (45). The model 
allows the detection of anti-inflammatory 
compounds that work by a variety of different 
mechanisms. Amongst the most active anti-
inflammatory extracts tested in this model was a 
sample prepared from the leaves and stems of the 
plant Dodonaea polyandra. The traditional use of 
D. polyandra (known traditionally as ‘Uncha’ by 
Kuuku I’yu traditional owners involved in the 
project) is to counteract pain, inflammation and 
discomfort associated with toothache and 
infection in the oral cavity. The laboratory in vivo 
result complemented the traditional use of Uncha. 
Ethanol was used as the initial extraction solvent 
for laboratory testing due to its ability to extract a 
broad range of plant secondary compounds. 
Traditionally the plant was not prepared as an 
extract but the plant material was used directly – 
held in the mouth, chewed or inserted into the 
hole following the removal of a tooth. This type 
of application could allow the release of a range 
of both lipophilic and more hydrophilic 
compounds into the saliva.  
The initial Western scientific results with 
extracts of D. polyandra consequently stimulated 
several years of intense research to uncover the 
chemical and mechanistic basis of the observed 
effect. To begin establishing the class(es) of 
constituents found in Uncha that might be 
responsible for this effect an activity-guided 
approach was undertaken. This technique which is 
widely used in natural products isolation, involves 
fractionating the extract based on the polarity of 
the constituents then testing fractions for 
bioactivity. Active fractions can be further 
separated and tested and pure active compounds 
eventually isolated. In vivo screening of solvent 
fractionated samples of D. polyandra ranging 
from low to high polarity was conducted. The 
results from this work (46) suggested secondary 
metabolites of non-polar nature were major 
contributors to the overall activity, whilst more 
polar constituents were contributing to a lesser 
extent. Activity-guided fractionation was 
conducted on lipophilic extracts of D. polyandra 
leaves in the same mouse ear oedema model of 
acute inflammation. The bioactivity was 
concentrated to within a small number of sub-
fractions obtained from chromatographic 
separation processes of the extract. Eventually, 
four benzoyl ester furanoclerodane diterpenoids 
were isolated, of which three were established as 
contributing a major part of the anti-inflammatory 
effects of the plant (47). 
The activity profiles for these compounds 
were determined via dose-response relationships, 
which revealed non-linear (biphasic) 
characteristics. The mechanism behind this 
phenomenon is often difficult to ascertain due to 
the multivariate nature of the response. However, 
such responses have potential to suggest possible 
molecular mechanisms for the compounds by 
noting other types of compounds known to give 
similar responses. Interestingly, glucocorticoid 
steroids are noteworthy examples known for 
displaying biphasic dose-response curves (48, 49). 
Whilst the full understanding behind the 
molecular mechanism of action of glucocorticoids 
is far from complete, it has been suggested that 
their ability to cause transrepression (transcription 
repression) and transactivation (transcription 
activation) of both pro- and anti-inflammatory 
genes (eg. cytokines and their receptors) could in 
part explain these trends (50-52). Understanding 
the mechanism of action of these diterpenoids 
compounds has been a primary focus of the most 
recent research due to initiation of commercial 
development pathways (see later). Understanding 
the chemical nature of the active compounds from 
a Western-scientific perspective was all very 
interesting, however traditional knowledge 
philosophy states that the effect is due to the 
whole plant (ie. all the constituents) and not a few 
single chemical entities. It is also viewed 
traditionally that disturbing the balance (ratio) of 
constituents can lead to the plant losing 
pharmacological effects. As mentioned above, this 
research is grounded in complementing the 
traditional knowledge and use of medicinal plants 
within the Kuuku I’yu traditional medicine 
system rather than proving it right or wrong. 
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Figure 3 Anti-inflammatory diterpenoids isolated from D. polyandra 
 
It could not be ruled out that other constituents 
within D. polyandra might be playing a 
supportive role for the observed anti-
inflammatory activity either through some 
additive anti-inflammatory effects or through 
effects on the distribution or clearance of the 
active diterpenoid compounds. Additional 
chemical analyses undertaken of ‘less-active’ 
fractions revealed the presence of a number of 
prenylated and non-prenylated flavonoids (53). 
Interestingly, a kaempferol derivative isolated in 
that study has been previously reported as an 
inhibitor of carrageenan-induced hind paw 
oedema and shown to be a potent anti-nociceptive 
agent in mice (54). The flavonoid class of 
secondary metabolites and in particular 
derivatives containing prenylated side chains are 
consistent with other studies conducted on related 
species within the Dodonaea genus where similar 
compounds have been identified (55-57). One of 
the main features of these compounds is their 
lipophilicity. Lipophilic compounds tend to be 
transported across the skin or mucous membranes 
better than hydrophilic compounds and may 
therefore have the ability to have effects in the 
local tissues or to enter the circulation. The 
particular activities of the flavonoids isolated 
from D.polyandra remain to be explored, but 
prenylated flavonoids have been found to exert a 
variety of physiological effects due to their 
affinity for biological membranes and protein 
targets such as enzymes (58). 
A direction this research is heading towards is 
the development of commercial medicinal 
products that contain or are derived from the plant 
products used in Kuuku I’yu traditional medicine. 
The discovery of the potent anti-inflammatory 
compounds from D. polyandra led to discussions 
with Kuuku I’yu traditional owners relating to the 
commercial prospects of such compounds and/or 
the extracts derived from the species. As part of 
this work is also centred on protecting Indigenous 
traditional knowledge, efforts were made to 
initiate protecting existing and new Intellectual 
Property via provisional patent applications in 
2009 and subsequent Patent Co-operation Treaty 
(PCT) applications leading to National Phase 
Filing in 2012 in several countries including the 
United States, countries of the European Union, 
China and others (59). This process was a 
landmark achievement in the history of the 
research from several points of view. Firstly, 
recognition and protection of the traditional 
knowledge involved, acknowledgment of 
traditional owners as inventors including a 
deceased focal Kuuku I’yu ancestor. Most 
importantly the Chuulangun Aboriginal 
Corporation and University of South Australia are 
joint applicants of the patent which signifies the 
ongoing commitment that Western researchers 
have in ensuring Indigenous researchers and their 
community benefit equally from the research 
being conducted. 
In the event of a saleable product being 
brought to market, how raw material will be 
supplied and processed is an obvious question that 
researchers have started investigating. In keeping 
with Indigenous ecological practices, the most 
fitting approach is to have raw plant material bush 
harvested by members of the Indigenous 
community, as opposed to controlled cultivation 
methods. This approach would create employment 
opportunities for the community to be involved in 
the field work, aligning with other aims and 
desirable outcomes for our research. A similar 
commercialisation case to this exists between 
Jarlmadangah Burru Aboriginal Corporation and 
Eskitis Institute – Griffith University, Queensland 
related to a plant with pain relieving properties 
known as the Marjala plant (mentioned earlier) 
(42). In 2008, both parties entered into a 
commercialisation agreement with biotechnology 
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company Avexis. Whilst our research does not yet 
have a commercial industry partner, a point of 
difference between the two cases is that the 
Avexis agreement outlines the opportunity for 
Jarlmadangah Burru Aboriginal Corporation to 
cultivate and supply raw material, instead of bush 
harvest. 
From the perspective of Kuuku I’yu 
traditional owners horticulture and cultivation 
style practices are not consistent with Indigenous 
land management practice and philosophy.  Plant 
materials need to be wild harvested by people 
who have been authorised under Indigenous 
governance and law in order for the medicine to 
have the proper medicinal effect. Further, 
unauthorised use of particular plant medicines 
could contravene Indigenous law and could have 
negative consequences in terms of 
intergenerational transfer of traditional 
knowledge. 
The significant number of plants used by 
Kuuku I’yu people and their potential to be 
screened in a vast number of disease models 
suggests that there is a long future for this 
collaboration. As such, it is envisaged that new 
opportunities to protect intellectual property will 
arise. Aside from patents, future intellectual 
property protection strategies may include looking 
at the appropriateness of trademarking. 
Trademarks may allow a product to be linked to a 
particular culture and geographical region. One 
issue which arises in the patenting process is the 
concern that other communities may use D. 
polyandra for different purposes or use different 
parts of the plant. Depending on the scope of 
claims granted within the patent, this could 
prevent any other communities from exploring the 
full scope of their own commercial projects 
related to that species. Chuulangun Aboriginal 
Corporation is also exploring other options for 
protecting Indigenous knowledge about natural 
resources more broadly in a way that recognises 
the geographical region and the natural resources 
and people that belong to it. This is one of the 
many challenges and learning curves faced with 
this type of research, where Western intellectual 
property laws have not been developed to 
properly protect Indigenous intellectual property 
(35).  
Dodonaea polyandra fits within a unique sub-
group of plants whereby it grows as separate and 
distinct male and female individual plants, termed 
dioecious. This is in contrast to majority of 
flowering plants which are bisexual, that is 
containing a flower with both male and female 
reproductive units (60). During collections made 
on Northern Kaanju homelands, raw material 
from a positively identified male individual was 
obtained and brought back to the laboratory for 
chemical characterisation. Initial work indicated 
that the constituents within this male sample were 
significantly different to those previously 
identified during bioactivity-guided fractionation. 
On this occasion bioactivity did not guide 
fractionation of the plant constituents, instead we 
aimed to identify the major components present. 
The study led to isolation and structural 
elucidation of several labdane diterpenoids, a 
subgroup of the diterpenoid class that is 
biosynthetically related to the clerodane type 
mentioned earlier (61). In the same manner that 
the prenylated flavonoids appear to be common in 
the genus Dodonaea, labdane diterpenoids have 
been regularly identified in other species of the 
genus (62-64). While the bioactivity of this 
sample remains to be tested, the chemistry of this 
male individual is quite unique. Of interest was 
that the clerodane diterpenoids identified 
previously were not detected in this male 
individual, giving the possibility of distinct 
differences between male and female individuals 
of this species. A novel labdane diterpenoid 
containing a rare seven-membered cyclic ether 
functionality was found (61). Analogous 
compounds have only been yielded via synthetic 
methods (65) and a brominated derivative 
identified from a marine algae (66). Hence, the 
discovery of such a molecule from a terrestrial 
source is of great significance. It also exemplifies 
the significance of Australian medicinal plants as 
an untapped source of novel chemical scaffolds. 
Whilst the traditional use of many Australian 
plants have been published in sources including 
Aboriginal pharmacopoeias and other books of 
similar nature (13, 67), much of the Western 
scientific properties of these plants remains to be 
unravelled. 
The focus of the most recent work has 
involved probing the mechanism of action of the 
clerodane diterpenoid compounds formerly 
identified. No work from this study has been 
published at the time of writing and therefore 
discussion will be kept to a general nature. The 
compounds were tested for inhibition of 
cyclooxygenase (COX)-1 and 2 enzyme activity. 
However, results from this test was negative 
implying the compounds were not COX 
inhibitors. Given the complex nature of the 
inflammation process and a lack of knowledge 
regarding the mechanisms of the anti-
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inflammatory compounds, initial work has 
focused on determining what effect the 
compounds have on cytokine production in both 
immunological and skin cells. The chosen 
direction is a reflection of the in vivo model used 
for guiding the initial activity where immune cells 
(eg. monocyte/macrophage) and skin cells (eg. 
keratinocyte) act in concert to release cytokines 
that are known to give rise to the inflammatory 
response following induction (with TPA). To date, 
data from both in vitro and in vivo experimental 
conditions suggest that several pro-inflammatory 
cytokines and cytokines involved in skin 
proliferation processes are implicated. Protein 
kinase C which is activated by TPA (68) and 
responsible for transducing the inflammatory 
response cascade in the TPA-induced mouse ear 
oedema model has been ruled out as a target, with 
negative results obtained from screening one of 
the active compounds against all isoforms of this 
kinase. Time-response data obtained in earlier in 
vivo work suggests that the compounds are acting 
at an early stage of the inflammatory response, as 
indicated by a shallower slope of the data line 
(Figure 4) (69). In this particular animal model 
steroid-like compounds often give similar patterns 
of data, in contrast to NSAID compounds which 
often show a delayed response and hence a 
steeper slope in the early stages (ie. Treatment and 
control data overlap until after several hours have 
passed). Continuing work in this area may look at 
exploring gene expression profiles which might 
help to shed light on the proinflammatory genes 
affected when cells are treated with the clerodane 
diterpenoids. 
Efforts to explore the development of D. 
polyandra as a commercial medicinal product 
have included the preparation of prototype 
formulations containing both a crude extract and 
pure ‘active’ compounds. This work 
(unpublished) has involved the use of in vitro 
techniques aimed at optimising the characteristics 
of an appropriate semi-solid dosage form 
including physicochemical stability and drug 
release with subsequent confirmation in vivo for 
bioactivity. These prototypes have demonstrated 
some success in mouse studies and are now 
progressing towards being tested in different 
models of skin inflammation to assess their 
efficacy and 3D skin models to assess toxicity and 
irritancy. 
 
 
 
 
Figure 4 Time-response data of active compounds 2 and 4 (from Figure 3) showing slope of treatment curves 
shallower than TPA control curve, indicating compounds are acting on the early response of the inflammatory process. 
( = TPA control (2.5 g/ear),  = compound 2 (0.88 mol/ear),  = compound 4 (0.9 mol/ear) and  = 
betamethasone-17,21-dipropionate (0.9 mol/ear)). 
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It must be recognised in the Western scientific 
testing of plants used in traditional medicine that 
there are often some fundamental limitations in 
the conclusions that can be drawn. Placing a plant 
extract into a laboratory-based test removes it 
from the context in which it is used in traditional 
medicine including the spiritual and cultural 
aspects of use. A plant extract produced in a 
laboratory will never contain the exact blend of 
plant chemicals that will be available when the 
plant is being used directly by a person in their 
traditional medicine system. Aspects of plant 
compound absorption and metabolism are very 
difficult to replicate in the laboratory and are 
completely absent in most initial screening tests to 
identify plants of interest from a Western 
scientific perspective. While we have gone some 
way in gaining a Western scientific understanding 
of the medicinal activity of Dodonaea polyandra, 
and how this complements Kuuku I’yu 
understandings of the plant’s effects, there is still 
the need for more detailed studies of how the 
plant actually works in the traditional use setting. 
Often our research priorities have been driven by 
the potential commercial development of the plant 
extracts and the need to meet expectations of 
potential commercial partners and medicine 
regulatory authorities. 
 
CONCLUSION 
 
Whilst this collaboration has developed a model 
which describes one approach to be used in 
conducting medicinal plant research involving 
Indigenous partners, we are reminded that the 
process should be constantly evolving and 
adapted to ensure continued growth of research 
outcomes. 
In terms of the broader picture in the 
investigation of Australian Aboriginal medicinal 
plants, there is no time like the present. Australia 
is positioned as one of the megadiverse countries 
in the world. There are species growing in areas 
occupied by Indigenous populations which have 
had no Western-scientific evaluations conducted 
on them. A number of Indigenous groups are 
examining ways to develop their medicinal plant 
resources that will provide opportunities to ensure 
the future existence of their people and culture. 
We have described some of the Western scientific 
outcomes using a research model where 
Aboriginal people actively participate as 
researchers in locally initiated and driven 
medicinal plant research. As the project moves 
forward it is envisaged that this will lead to the 
development of novel plant-based commercial 
products which will help to facilitate the 
reoccupation of traditional homelands via 
community operated business enterprises and 
sustainable management of these lands. The 
blending of Indigenous and Western scientific 
methodology is serving as a bridge to ensure the 
success of this vision. No singular, detailed model 
or approach exists for addressing these issues and 
any way forward will need to be developed in 
conjunction with Aboriginal people in particular 
places in a local context. Models for Aboriginal 
participation and developing cross-cultural 
collaboration will inevitably vary from place to 
place. If there is one aspect of any future model 
which should be inherent in its design, it is that 
there continues to be learning from both sides. 
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